Search clinical trials for: JI-101

Total 6064 results

Poseida Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
University of Zurich
KKS Netzwerk; Foundation Wings For Life; Horizon 2020 - European Commission; State... and other collaborators

Completed

NISCI - Nogo Inhibition in Spinal Cord Injury (NISCI)

Spinal Cord Injury, Acute

Czechia, Germany, Spain, Switzerland
Iltoo Pharma

Completed

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) (LUPIL-2)

Systemic Lupus Erythematosus

France, Spain, Mexico, Austria, Germany, Bulgaria, Italy, Mauritius, Portugal, Romania
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 in Pancreatic Cancer

Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States, Australia
Curis, Inc.

Completed

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Non-Small Cell Lung Cancer | Liver Cancer

United States
Lantheus Medical Imaging

Withdrawn

Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing (LMI1195-201)

Heart Failure

United States
Tranzyme, Inc.

Completed

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

Diabetes Mellitus | Gastroparesis

United States, Denmark, Norway, Sweden, United Kingdom, India
Functional Genetics Inc.
United States Department of Defense

Unknown

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)

Influenza

United States
Tranzyme, Inc.

Completed

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis

Diabetes Mellitus | Gastroparesis

Sweden, Denmark
International AIDS Vaccine Initiative
Coalition for Epidemic Preparedness Innovations

Recruiting

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Lassa Fever

Ghana, Liberia, Nigeria
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
Monopar Therapeutics

Recruiting

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Urothelial Carcinoma | Triple-negative Breast Cancer | Solid Tumor, Adult

Australia
Incyte Corporation

Recruiting

Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

Advanced Malignancies

Spain, United States, France, Belgium, Italy
Washington University School of Medicine
Cue Biopharma

Recruiting

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Oropharyngeal Squamous Cell Carcinoma

United States
Inhibrx, Inc.

Completed

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (rhAAT-Fc)

Alpha-1 Antitrypsin Deficiency | AATD

United States, New Zealand, United Kingdom
ISOThrive Inc.

Completed

Open Label Tolerability Study of ISOThrive Prebiotic Nectar (MIMO) in Subjects With Constipation

Constipation

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Minerva Neurosciences

Completed

A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers

Healthy Subjects

Ireland
Kythera Biopharmaceuticals

Completed

ATX-101 Abdominoplasty (ATX-101-08-10)

Characteristics of Subcutaneous Fat

United States
Blue Blood Biotech Corp.

Recruiting

Phase II Study of BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

Diabetic Foot Ulcer

Taiwan
ORIC Pharmaceuticals

Terminated

Study of ORIC-101 in Combination With Enzalutamide

Prostatic Neoplasms

United States
Immodulon Therapeutics Ltd

Terminated

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Malignant Melanoma

United Kingdom
Editas Medicine, Inc.

Active, not recruiting

Single Ascending Dose Study in Participants With LCA10

Retinal Degeneration | Eye Diseases, Hereditary | Vision Disorders | Leber Congenital Amaurosis 10 | Inherited Retinal Dystrophies | Retinal Disease | Eye Disorders Congenital

United States
Terns, Inc.

Completed

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Gate Neurosciences, Inc

Terminated

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

Major Depressive Disorder | Excessive Sleepiness

United States
R-Tech Ueno, Ltd.

Completed

A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye

Dry Eye

United States
Kythera Biopharmaceuticals

Completed

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Healthy

United States
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive
Aerovate Therapeutics

Recruiting

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) (IMPAHCT-FUL)

Pulmonary Arterial Hypertension

United States, Belgium, Italy, Spain, Australia, Canada, China, Singapore, France, United Kingdom, Latvia, Mexico, Argentina, Israel, South Africa, Chile, Poland, Germany, Portugal, Colombia
Novartis Pharmaceuticals

Active, not recruiting

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam (STRENGTH)

Spinal Muscular Atrophy

Japan, Belgium, Spain, Canada, United States, Australia, Italy, France, Netherlands
NYU Langone Health

Completed

Teachers Thriving Together

Social Emotional Competence

United States
Impatients N.V. trading as myTomorrows
Immodulon Therapeutics Ltd

No longer available

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Stage IV | Pancreas Cancer | Pancreatic Cancer Stage III

France, United Kingdom
Spyryx Biosciences, Inc.

Completed

A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Cystic Fibrosis

Canada
Kythera Biopharmaceuticals

Completed

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

Healthy

United States
MGB Biopharma Limited
Hammersmith Medicines Research; Innovate UK; Cambridge Regulatory Services; Phases... and other collaborators

Completed

Safety, Blood Levels and Effects of MGB-BP-3

Healthy
Kythera Biopharmaceuticals

Completed

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

Healthy

United States
Seoul National University Hospital
Pharos iBio Co., Ltd.

Recruiting

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) (CREATIVE)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma

Korea, Republic of
EpicentRx, Inc.

Recruiting

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (KEVLARx)

Oral Mucositis

United States
MorphoSys AG

Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, United Kingdom, Austria, Germany, Italy, Poland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Assessment of LBR-101 In Chronic Migraine

Chronic Migraine

United States
Cambium Medical Technologies LLC
University of Michigan; Duke University; Oregon Health and Science University; Stanford... and other collaborators

Completed

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

Dry Eye | Graft-versus-host-disease | Ocular Discomfort

United States
Gilead Sciences

Active, not recruiting

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

B-cell Malignancies

United States, United Kingdom, France
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, France, Spain, Poland, United Kingdom, Australia, Belgium, Canada
Aerovate Therapeutics

Recruiting

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) (IMPAHCT)

Pulmonary Arterial Hypertension

United States, Belgium, Italy, Spain, Australia, Canada, China, Poland, Singapore, Argentina, United Kingdom, France, Israel, Latvia, Austria, Mexico, Puerto Rico, Sweden, South Africa, Netherlands, Chile, Germany, Greece, Portugal, Cze... and more
Excision BioTherapeutics

Active, not recruiting

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

HIV-1-infection

United States
Amyndas Pharmaceuticals S.A.

Unknown

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) (SAVE)

Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
Lumen Bioscience, Inc.

Completed

Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers

Campylobacter Jejuni Infection

Australia
Bellicum Pharmaceuticals
M.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaborators

Completed

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Castrate Resistant Prostate Cancer (CRPC)

United States
Aclaris Therapeutics, Inc.

Completed

An Open-Label Safety Study of A-101 Solution

Seborrheic Keratosis

United States

Search clinical trials for: JI-101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations